1-14 of 14
Paul G. Richardson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

Sagar Lonial, Shambavi Richard, Jeffrey V Matous, Andrew J. Yee, Urvi Shah, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Sikander Ailawadhi, Paul G. Richardson, Manisha Bhutani, Samantha Perino, Jason Kirby, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, Matthew Schnaderbeck, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Amanda Hoerres, Stewart L. Fisher, Roy M. Pollock, Adam Crystal, Michelle Mahler, Jesus Bardeja
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT186.
https://doi.org/10.1158/1538-7445.AM2022-CT186
Published: 15 June 2022
View articletitled, Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
Journal Articles

Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)

Paul G. Richardson, Albert Oriol, Alessandra Larocca, Paula Rodriguez Otero, Jan Moreb, Joan Bladé, Hani Hassoun, Michele Cavo, Adrián Alegre, Amitabha Mazumder, Christopher Maisel, Agne Paner, Xavier Leleu, Jeffrey A. Zonder, Johan Harmenberg, Sara Thuresson, Hanan Zubair, María-Victoria Mateos
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2019-CT154
Published: 01 July 2019
View articletitled, Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
Journal Articles

Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)

Ludek Pour, Yvonne Efebera, Miquel Granell, Roman Hajek, Albert Oriol, Jacques Delaunay, Katell Le Du, Jean-Richard Eveillard, Lionel Karlin, Vladimir Maisnar, Joaquin Martinez-Lopez, María-Victoria Mateos, Jan Moreb, Vincent Ribrag, Paul G. Richardson, Jan Straub, Catriona Byrne, Christian Jacques, Hanan Zubair, Enrique Ocio
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT080.
https://doi.org/10.1158/1538-7445.AM2019-CT080
Published: 01 July 2019
View articletitled, Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
Journal Articles

Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential

Tarek H. Mouhieddine, Jihye Park, Robert Redd, Christopher J. Gibson, Salomon Manier, Amin Nassar, Kalvis Hornburg, Marzia Capelletti, Daisy Huynh, Romanos Sklavenitits Pistofidis, Mark W. Bustoros, Saud H. AlDubayan, Brendan Reardon, Cody J. Boehner, Henry Dumke, Chia-Jen Lui, Darlys Schott, Eliezer M. Van Allen, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, David P. Steensma, Jacob P. Laubach, Paul G. Richardson, Jerome Ritz, Benjamin L. Ebert, Robert J. Soiffer, Donna Neuberg, Irene M. Ghobrial
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2954.
https://doi.org/10.1158/1538-7445.AM2018-2954
Published: 01 July 2018
View articletitled, Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential
Journal Articles

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies

Larry D. Anderson, James Cavet, Adam D. Cohen, Yan Y. Degenhardt, Catherine E. Ellis, Fiona Germaschewski, Nikoletta Lendvai, Edward Libby, Joanna Opalinska, Rakesh Popat, Isabelle Pouliquen, Paul G. Richardson, Keith E. Stockerl-Goldstein, Heather J. Sutherland, Suzanne Trudel, Peter M. Voorhees, Jeffrey Wetherington
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT034.
https://doi.org/10.1158/1538-7445.AM2016-CT034
Published: 15 July 2016
View articletitled, Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies
Journal Articles

Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia

Jana Jakubikova, Danka Cholujova, Teru Hideshima, Jacob Laubach, Nikhil C. Munshi, Steven P. Treon, Paul G. Richardson, Efstathios Kastritis, David M. Dorfman, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2004.
https://doi.org/10.1158/1538-7445.AM2015-2004
Published: 01 August 2015
View articletitled, Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia
Journal Articles

Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Naoya Mimura, Teru Hideshima, Toshiyasu Shimomura, Rikio Suzuki, Hiroto Ohguchi, Ola Rizq, Shohei Kikuchi, Yasuhiro Yoshida, Francesca Cottini, Jana Jakubikova, Diana Cirstea, Gullu Gorgun, Jiro Minami, Yu-Tzu Tai, Paul G. Richardson, Teruhiro Utsugi, Atsushi Iwama, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2014) 74 (16): 4458–4469.
https://doi.org/10.1158/0008-5472.CAN-13-3652
Published: 13 August 2014
View articletitled, Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
Open the PDF for Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition in another window
Includes: Supplementary data
Journal Articles

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Cancer Research
Cancer Res (2009) 69 (14): 5835–5842.
https://doi.org/10.1158/0008-5472.CAN-08-4285
Published: 15 July 2009
View articletitled, Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Open the PDF for Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 in another window
Includes: Supplementary data
Journal Articles

Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

Constantine S. Mitsiades, Enrique M. Ocio, Atanasio Pandiella, Patricia Maiso, Consuelo Gajate, Mercedes Garayoa, David Vilanova, Juan Carlos Montero, Nicholas Mitsiades, Ciaran J. McMullan, Nikhil C. Munshi, Teru Hideshima, Dharminder Chauhan, Pablo Aviles, Gabriel Otero, Glynn Faircloth, M. Victoria Mateos, Paul G. Richardson, Faustino Mollinedo, Jesus F. San-Miguel, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2008) 68 (13): 5216–5225.
https://doi.org/10.1158/0008-5472.CAN-07-5725
Published: 01 July 2008
View articletitled, Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
Open the PDF for Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo in another window
Includes: Supplementary data
Journal Articles

FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance

Hiroshi Yasui, Teru Hideshima, Noopur Raje, Aldo M. Roccaro, Norihiko Shiraishi, Shaji Kumar, Makoto Hamasaki, Kenji Ishitsuka, Yu-Tzu Tai, Klaus Podar, Laurence Catley, Constantine S. Mitsiades, Paul G. Richardson, Rainer Albert, Volker Brinkmann, Dharminder Chauhan, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2005) 65 (16): 7478–7484.
https://doi.org/10.1158/0008-5472.CAN-05-0850
Published: 15 August 2005
View articletitled, FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
Open the PDF for FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance in another window
Journal Articles

Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib

Klaus Podar, Reshma Shringarpure, Yu-Tzu Tai, Melissa Simoncini, Martin Sattler, Kenji Ishitsuka, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2004) 64 (20): 7500–7506.
https://doi.org/10.1158/0008-5472.CAN-04-0124
Published: 15 October 2004
View articletitled, Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib
Open the PDF for Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib in another window
Journal Articles

Antitumor Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitors, a Novel Class of Agents, in Multiple Myeloma

Teru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, Klaus Podar, Masaharu Akiyama, Constantine Mitsiades, Nicholas MItsiades, Baoqing Gong, Lynn Bonham, Peter de Vries, Nikhil Munshi, Paul G. Richardson, Jack W. Singer, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2003) 63 (23): 8428–8436.
Published: 16 December 2003
View articletitled, Antitumor Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitors, a Novel Class of Agents, in Multiple Myeloma
Open the PDF for Antitumor Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitors, a Novel Class of Agents, in Multiple Myeloma in another window
Journal Articles

Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model

Richard LeBlanc, Laurence P. Catley, Teru Hideshima, Suzanne Lentzsch, Constantine S. Mitsiades, Nicholas Mitsiades, Donna Neuberg, Olga Goloubeva, Christine S. Pien, Julian Adams, Deepak Gupta, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2002) 62 (17): 4996–5000.
Published: 01 September 2002
View articletitled, Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model
Open the PDF for Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model in another window
Journal Articles

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment

Boris Lin, Klaus Podar, Deepak Gupta, Yu-Tzu Tai, Sigui Li, Edie Weller, Teru Hideshima, Suzanne Lentzsch, Faith Davies, Cheng Li, Ellen Weisberg, Robert L. Schlossman, Paul G. Richardson, James D. Griffin, Jeanette Wood, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2002) 62 (17): 5019–5026.
Published: 01 September 2002
View articletitled, The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment
Open the PDF for The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment in another window